Search

everythinglearnresearchcommunity

for

Search:↓

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.

The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.

The user has been using oral minoxidil and topical finasteride for over a year with good results but is considering adding mesotherapy with dutasteride due to concerns about side effects and is seeking advice. Another user suggests continuing with oral finasteride or dutasteride, while another supports mesotherapy for its benefits and professional oversight.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

The user is considering alternatives to topical minoxidil for hair growth due to concerns about future cat ownership, mentioning stemoxydine and redensyl as possibilities. They currently use topical regaine foam and oral finasteride.

Minoxidil and finasteride may cause different shedding patterns; the user experienced shedding with finasteride which stopped, and is now concerned about potential shedding after starting minoxidil. They have been on finasteride for 3 months, minoxidil for 1 week, and had exosome therapy 1 month ago.

The user reports noticeable hair growth after 5 weeks using finasteride, minoxidil, dermarolling, and ketoconazole. They seek confirmation of their progress and question if they are a hyper responder.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.

The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.

The conversation discusses the effectiveness of adding RCP (redensyl, capixyl, procapil) to a hair loss treatment regimen that includes minoxidil and finasteride. Users share experiences, suggesting RCP may not be as effective as minoxidil, but could be useful for creating topical solutions.

The user is considering using Tacrolimus Solution and topical Dutasteride to avoid shedding caused by Minoxidil, which they fear may lead to facial side effects. They are also concerned about scalp sensitivity and are exploring different treatment bases to manage seborrheic dermatitis.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

Finasteride may cause elevated liver enzymes, potentially leading to liver issues, though this is rare. Users should monitor liver function and consider topical alternatives if liver sensitivity occurs.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.

The user experienced hair improvement using a topical finasteride, minoxidil, and tretinoin combo, along with supplements like zinc, copper, magnesium, vitamin D3, K2, iodine, and boron. They believe these changes are due to addressing mineral deficiencies and possibly thyroid issues, despite skepticism from others.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The user switched from finasteride to dutasteride and is seeking feedback on hair changes after 4 months. The current regimen includes oral dutasteride, oral minoxidil, and topical minoxidil.

A 35-year-old man shares his positive progress in hair regrowth using a daily routine of 5mg oral minoxidil and 0.5mg dutasteride, along with a low light cap, weekly dermarolling, and biweekly ketoconazole shampoo. He reports noticeable improvements without side effects and aims to inspire others considering similar treatments.

A user experienced increased testosterone and estradiol levels after starting finasteride/dutasteride and is asking if these levels will return to normal over time. The conversation focuses on whether these changes are temporary.

The user experimented with finasteride to reduce hair loss and plans to test if creatine affects DHT levels while on finasteride. Initial results showed low DHT levels, indicating finasteride's effectiveness, with further tests planned for creatine's impact.

The user experienced noticeable hair regrowth after using finasteride for 2 years, oral minoxidil for 1 year, and recently starting dermarolling. The right temple shows significant improvement, while the left remains similar.

A user questions if a topical compound with finasteride, dutasteride, minoxidil, retinoic acid, caffeine, and triamcinolone is excessive for hair loss treatment. Another user shares their experience using topical finasteride without issues and notes that alternating finasteride and dutasteride is common.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The conversation humorously discusses two resilient hair strands that resist DHT, with mentions of minoxidil and finasteride as ineffective treatments. Users joke about cloning the hairs and the mystery of baldness.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

Switching from finasteride to dutasteride can reduce scalp DHT levels more effectively. The discussion includes using minoxidil, finasteride, and RU58841 for hair loss treatment.

The conversation is about a user experiencing hair shedding after switching from finasteride to dutasteride and increasing their oral minoxidil dose. The user is advised to continue with the current treatment, consider adding topical minoxidil, and consult a dermatologist for potential underlying issues.

The user is using a hair loss treatment with finasteride 0.1%, minoxidil 5%, and tretinoin 0.01%, applied once daily at 1ml. They are questioning if a 60ml bottle used twice daily implies a higher recommended dose despite the same 5% minoxidil concentration.